Intelligent Bio Solutions Reports Preliminary Unaudited Fiscal Q3 Results
Intelligent Bio Solutions Sees Prelim. Q3 2024 Revenue $0.82M Vs $1.190M Est.
Intelligent Bio Solutions Sees Prelim. Q3 2024 Revenue $0.82M Vs $1.190M Est.
Intelligent Bio Solutions Sees 3Q Rev of Around $820,000>INBS
Intelligent Bio Solutions Sees 3Q Rev of Around $820,000>INBS
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprint
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio With Grant of New European Patent With Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
Looking Into Intelligent Bio Solutions's Recent Short Interest
Intelligent Bio Solutions's (NYSE:INBS) short percent of float has risen 57.64% since its last report. The company recently reported that it has 90 thousand shares sold short, which is 3.2% of all reg
Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
Intelligent Bio Solutions Inc Files For Offering Of Up To 6.8M Shares By The Selling Stockholders
Intelligent Bio Solutions Inc Files For Offering Of Up To 6.8M Shares By The Selling Stockholders
Press Release: Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("IN
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
Press Release: Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) shares increased by 144.6% to $2.74 during Friday's pre-market session. The company's market cap stands at $12.8 million. Psyence Biomedical (NASDAQ:PBM) stock moved upwards
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing
Intelligent Bio Solutions Partners With Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
Peering Into Intelligent Bio Solutions's Recent Short Interest
Intelligent Bio Solutions's (NYSE:INBS) short percent of float has risen 165.35% since its last report. The company recently reported that it has 73 thousand shares sold short, which is 10.11% of all
Intelligent Bio Solutions Inc. Regains Compliance With Nasdaq Minimum Bid Price Requirement and Confirms Compliance With Minimum Stockholders' Equity Requirement
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing
VUZI, TCBP and MANU Among Pre-market Losers
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersSeaStar Medical Holding (NASDAQ:ICU) shares rose 27.9% to $1.1 during Monday's pre-market session. The company's market cap stands at $71.6 million. Aesthetic Medical Intl (NASDAQ:AIH) shares i
No Data